CompletedNot Applicable

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Germany9,571 participantsStarted 2019-09-16

Plain-language summary

Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at least one inpatient T2DM diagnosis (ICD E11) * At least one prescription of an empagliflozin-containing antidiabetic drug: Jardiance® (Empagliflozin, ATC A10BK03, former A10BX12) or Synjardy® (Empagliflozin/ Met¬for¬min, ATC A10BD20) Exclusion Criteria: * Any diagnosis of T1DM

What they're measuring

Percentage of Participants With Previous Occurence of Cardiovascular Comorbidities

Timeframe: At baseline.

Percentage of Participants With Previous Occurence of Other Typical Diabetes Complications

Timeframe: At baseline.

Percentage of Participants With Antidiabetic and Cardiovascular Co-medication

Timeframe: At baseline.

Trial details

NCT IDNCT04098575

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-12-31

Results submitted2020-12-21

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials